GE Marquette to market CardioDynamics digital monitors:
This article was originally published in Clinica
Executive Summary
GE Marquette Medical Systems is to get exclusive rights to market and sell CardioDynamics BioZ non-invasive digital cardiac output monitoring systems to hospitals in certain European countries, including France, Germany, Belgium, the Netherlands and Luxembourg. GE Marquette will buy an initial $714,000 worth of CardioDynamics' BioZ.com systems and accessories. Under the terms of the agreement, the two companies will also co-operate in technology integration. San Diego California-based CardioDynamics' BioZ system will complement GE Marquette's cardiology management system, CardioIntelligence.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.